Four intranasal peptide arms at simulated 4,500 m
N. N. Karkishchenko, V. V. Uyba, V. N. Karkishchenko, E. B. Shustov, K. V. Kotenko, S. L. Lyublinskiy · 2014 · Essays on Sports Pharmacology, Vol. III, Vectors of Pharmacoregulation, Chapter 7, pp. 177–180, Table 12
Indexed 2026-11-09.
Related evidence maps: Military & occupational ↗
Reported findings and study design
Thymogen was associated with lower lactate during the chamber protocol. Cortexin showed longer complex reaction latency alongside other physiological changes. The endpoints were heterogeneous.
Author-described random assignment. Exposure for 60–80 min at simulated 4,500 m with postural testing, a three-minute 100 W cycling load, motor tasks and blood measurements.
Dose, route and schedule
Single intranasal administration one hour before ascent: Thymogen 1 µg, Cortexin 10 mg, Epithalamin 10 mg or Prostatilen 5 mg. The control received equivalent-volume saline.
Protocol source ↗ · Original publication and selected methods and results checked
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Thymogen · blood lactate | 1.81±0.21 vs 2.98±0.46 | Source Table 12 units not specified on the row. · p<0.05 versus saline |
| Cortexin · complex visuomotor reaction latency | 423±12 vs 381±9 ms | Slower response, even with some favorable markers. · p<0.01 versus saline |
| Epithalamin · number of complaints | 0.33±0.13 vs 1.4±0.5 | Authors marked a trend. · p<0.1 versus saline |
| Prostatilen · number of complaints | 0.2±0.2 vs 1.4±0.5 | Small short-term comparison. · p<0.05 versus saline |
The 4,500 m protocol differs from Cheprasov’s 5,000 m comparison. Participant independence has not been established and this series adds no people to the historical tally.
Source for the extracted data ↗ · Checked 2026-11-09
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Small arms, numerous endpoints and several comparisons reported at p<0.1. Exact allocation counts and overlap with the Medilab lineage remain unresolved.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original publication and selected methods and results checked
Review depth: Reported methods, results and evidence limitations
Source access and review scope
Original publication and selected methods and results checked
Recorded source-check date: 2026-11-09. This date does not imply a completed systematic review.
Source type: Essays on Sports Pharmacology, Vol. III, Vectors of Pharmacoregulation, Chapter 7, pp. 177–180, Table 12
Citation and original source
Original source: N. N. Karkishchenko, V. V. Uyba, V. N. Karkishchenko, E. B. Shustov, K. V. Kotenko, S. L. Lyublinskiy. Four intranasal peptide arms at simulated 4,500 m Essays on Sports Pharmacology, Vol. III, Vectors of Pharmacoregulation, Chapter 7, pp. 177–180, Table 12 2014.
Molekul research summary: https://molekul.io/research/shustov-volume3-human-hypoxia-2014. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entryRelated compound profiles
Thymogen
EW is discussed in the thymus-derived research program. Thymalin extract outcomes cannot be assigned to this defined peptide.
Cortexin
A tissue-derived preparation with Russian stroke, cognitive, pediatric and other clinical reports. Study designs vary; the independent stroke review is shown alongside favorable original reports. None validates the personal WHOOP diary.
Epithalamin
A pineal-gland tissue extract containing a mixture of peptides. Human aging and melatonin studies of this preparation must be distinguished from research on synthetic Epitalon (AEDG).
Prostatilen
A prostate-tissue-derived polypeptide preparation with historical urological clinical reports. It is distinct from the synthetic short peptide Prostamax.